Bank Hapoalim BM decreased its holdings in shares of Opko Health, Inc. (NASDAQ:OPK) by 44.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,510 shares of the biotechnology company’s stock after selling 32,825 shares during the period. Bank Hapoalim BM’s holdings in Opko Health were worth $278,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Financial Architects Inc lifted its position in Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 4,800 shares during the period. Blair William & Co. IL acquired a new stake in Opko Health in the second quarter valued at about $112,000. Engineers Gate Manager LP acquired a new stake in Opko Health in the second quarter valued at about $117,000. Crossmark Global Holdings Inc. acquired a new stake in Opko Health in the third quarter valued at about $118,000. Finally, IFC Holdings Incorporated FL lifted its position in Opko Health by 16.5% in the second quarter. IFC Holdings Incorporated FL now owns 17,864 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 2,525 shares during the period. Institutional investors and hedge funds own 22.66% of the company’s stock.
WARNING: “Bank Hapoalim BM Sells 32,825 Shares of Opko Health, Inc. (OPK)” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://stocknewstimes.com/2017/11/16/bank-hapoalim-bm-sells-32825-shares-of-opko-health-inc-opk.html.
In other news, major shareholder Opko Health, Inc. bought 655,738 shares of the stock in a transaction on Monday, October 30th. The stock was purchased at an average cost of $3.05 per share, with a total value of $2,000,000.90. Following the purchase, the insider now owns 6,678,752 shares of the company’s stock, valued at $20,370,193.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Phillip Md Et Al Frost bought 12,000 shares of the stock in a transaction on Wednesday, August 23rd. The stock was purchased at an average cost of $6.13 per share, with a total value of $73,560.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $18,812,669.63. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 1,126,038 shares of company stock valued at $4,828,540. Insiders own 40.19% of the company’s stock.
A number of equities research analysts recently commented on the stock. Jefferies Group LLC restated a “hold” rating and issued a $8.00 price objective on shares of Opko Health in a research report on Thursday, July 27th. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, September 23rd. J P Morgan Chase & Co downgraded shares of Opko Health from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $12.00 to $7.00 in a research report on Thursday, September 14th. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $16.00 price target on shares of Opko Health in a research report on Monday, September 25th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Opko Health has a consensus rating of “Hold” and an average price target of $13.97.
Opko Health, Inc. (OPK) traded up $0.07 during mid-day trading on Thursday, hitting $4.81. 2,115,496 shares of the stock were exchanged, compared to its average volume of 4,537,633. Opko Health, Inc. has a 52 week low of $4.50 and a 52 week high of $12.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48.
Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The company had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. During the same quarter in the previous year, the business posted ($0.03) earnings per share. Opko Health’s revenue was down 11.6% on a year-over-year basis. analysts forecast that Opko Health, Inc. will post -0.27 earnings per share for the current year.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.